Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01625182 · ClinicalTrials.gov registry record · Phase 3
Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients.
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 106
- Enrollment target
NCT01625182 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 106 participants.
The verdict
NCT01625182, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 106 participants
- Enrollment target
Study Summary
The study was designed to evaluate the efficacy and safety of fingolimod in the treatment of chronic inflammatory demyelinating polyradiculoneuropathy compared with placebo.
Interventions
- DRUG Placebo Comparator
- DRUG Fingolimod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2012-12-22 |
| Est. Completion | 2016-09-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01625182
The ClinicalTrials.gov registry entry for NCT01625182 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Comparator is the first listed.
NCT01625182 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01625182 about?
NCT01625182 is a clinical study titled "Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients.". The study was designed to evaluate the efficacy and safety of fingolimod in the treatment of chronic inflammatory demyelinating polyradiculoneuropathy compared with placebo.
What is the current status of trial NCT01625182?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 106 participants. The study started on 2012-12-22. Estimated completion is 2016-09-03.
What interventions are being tested in trial NCT01625182?
The interventions under investigation include: Placebo Comparator (DRUG), Fingolimod (DRUG).
Who is sponsoring clinical trial NCT01625182?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.